EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
0.14
AUD
+0.00
(-3.45%)
ISIN
AU0000182552
Return %
Stock
S&P 500
1Y
-88.76
14.20
3Y
-78.92
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- John Graham McCutcheon
- Full Time Employees
- 135
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 480 Oakmead Parkway Sunnyvale CA United States 94085
- IPO Date
- Nov 23, 2021
- Website
- ebrsystemsinc.com
- Similar Companies
- Business
- EBR Systems, Inc. (EBR.AX) develops and commercializes the WiSE (Wireless Stimulation Endocardially) cardiac rhythm management system, a technology designed to provide physiologic pacing for heart failure patients by delivering wireless endocardial stimulation directly to the left ventricle. The company's core products and services include the WiSE-LV System, which comprises the WiSE Unit (a wireless, battery-less, ultrasound-powered pacing device), the Programmer (a non-implantable tool for device configuration), and associated delivery systems and implantation tools; it targets patients with heart failure, particularly those with cardiac resynchronization therapy non-responders, through minimally invasive implantation procedures. EBR Systems operates in the medical device industry, focusing on cardiac electrophysiology segments, with primary customers including hospitals, electrophysiologists, and cardiologists in North America, Europe, and Australia. Founded in 2002 and headquartered in Silicon Valley, California, USA, the company maintains global operations with regulatory approvals in the United States (PMA approval in 2021), the European Union (CE Mark), and Australia, supported by manufacturing facilities and clinical partnerships worldwide. Subsidiaries include EBR Systems Pty Ltd in Australia for regional operations, with no parent company. In the last 1-2 years, EBR Systems has advanced its market presence through key regulatory milestones, including expanded indications for the WiSE-LV System in Australia and ongoing post-market studies like the WiSE-CRT registry demonstrating improved clinical outcomes; strategic partnerships with leading cardiac centers for investigator-initiated trials; and a capital raise in 2024 to support commercialization expansion in the US and Europe, positioning the company for broader adoption in heart failure therapy.